The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with a history of sino-nasal surgery or for whom surgery is not advisable. This is the first approval for
Similar Posts
Pharmathen International S.A.11/21/2025 483
Pharmathen International S.A. 11/21/2025 483Sato Pharmaceutical Co., Ltd. – 11/21/2025
Sato Pharmaceutical Co., Ltd. – 11/21/2025. Country: Japan. Record Type: 483Wedgewood Connect, LLC. San Jose, CA. 483 issued 07/03/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 07/03/2025
Short Title (70 char) Wedgewood Connect, LLC. San Jose, CA. 483 issued 07/03/2025
FEI Number 3003434972
Firm Name Wedgewood Connect, LLC
Record Type 483
State CA
Establishment Type Outsourcing FacilitPeakMax may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use PeakMax, a product promoted and sold for sexual enhancement on various websites, including www.vitalityvita.com, and possibly in some retail stores.QuVa Pharma, Inc. Sugar Land, TX. Untitled Letter issued 06/18/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/18/2025
Short Title (70 char) QuVa Pharma, Inc. Sugar Land, TX. Untitled Letter issued 06/18/2025
FEI Number 3012053582
Firm Name QuVa Pharma, Inc
Record Type 483
State TX
Establishment Type Outsourcing FacileCTD Submission Standards for eCTD v3.2.2 and Regional M1
eCTD Submission Standards